Aktis Oncology, Inc. (AKTS) ownership: insiders 1% · institutions 64% · index and ETF funds 1% (13F 2026-03-31). Insider activity, 90 days: 9 sales, 0 open-market buys. SEC EDGAR first-party data.
| Holder | Shares | Market Value | % Outstanding | Reported |
|---|---|---|---|---|
| MPM Bioimpact LLC | 4835872.00 | $86.51M | 9.1% | 2026-03-31 |
| EcoR1 Capital, LLC | 4824469.00 | $86.31M | 9.0% | 2026-03-31 |
| Blue Owl Capital Holdings LP | 3161348.00 | $56.56M | 5.9% | 2026-03-31 |
| Wellington Management | 2317044.00 | $41.45M | 4.3% | 2026-03-31 |
| T. Rowe Price | 2123812.00 | $37.99M | 4.0% | 2026-03-31 |
| BlackRock | 2112127.00 | $37.79M | 4.0% | 2026-03-31 |
| RTW Investments, LP | 1592043.00 | $28.48M | 3.0% | 2026-03-31 |
| RA Capital Management, L.P. | 1503084.00 | $26.89M | 2.8% | 2026-03-31 |
| Insider | Transaction | Value | Date |
|---|---|---|---|
| Sell | null | 2026-07-20 | |
| Sell | null | 2026-07-20 | |
| Sell | null | 2026-07-20 | |
| Sell | null | 2026-07-20 | |
| Sell | null | 2026-07-20 | |
| Sell | null | 2026-07-20 | |
| Sell | null | 2026-07-17 | |
| Sell | null | 2026-07-17 |
Back to AKTS overview · AKTS earnings · All congressional trades
Institutional data from SEC Form 13F. Insider data from SEC Form 4. Congressional data from STOCK Act disclosures. Not personalized investment advice.